MedTrace Logo

Metabolic Imaging in Carotid Atherosclerosis

NCT01674257 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2024-05-02

No results posted yet for this study

Summary

Hardening of the arteries (atherosclerosis) is a common disorder that causes heart attacks and strokes. PET CT and contrast-enhanced MRI scans are two new ways of assessing atherosclerosis. The investigators propose to perform PET CT and MRI scans on patients with hardening of the neck arteries due to undergo surgery to remove the hardened areas. The investigators will then be able to compare the hot spots found on these scans with what the investigators can see in the removed specimens under the microscope in the laboratory. This will give investigators insight into the value of PET CT and MRI as tools for assessing atherosclerosis. It will also provide the investigators with new information relating to the underlying processes that give rise to atherosclerosis and will pave the way for the future development of new treatments.

Conditions

Interventions

OTHER

USPIO (ferumoxytol)-enhanced MRI scan

Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.

RADIATION

18f-Fluoride PET/CT scan

RADIATION

18F-Flurodeoxyglucose PET/CT scan

Sponsors & Collaborators

  • NHS Lothian

    collaborator OTHER_GOV

  • British Heart Foundation

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • David E Newby, DSc · University of Edinburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-10
Primary Completion
2014-06-30
Completion
2015-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01674257 on ClinicalTrials.gov